<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131052</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00038789</org_study_id>
    <nct_id>NCT01131052</nct_id>
  </id_info>
  <brief_title>Diabetes in the Elderly: Prospective Study</brief_title>
  <acronym>DMElderly</acronym>
  <official_title>Diabetes Care in Nursing Home Residents: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guillermo Umpierrez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is highly prevalent in the elderly, afflicting about 20% of older adults aged 65-75
      years and 40% of adults &gt;80years of age. It is expected that the number of elderly people
      suffering from diabetes will increase in the future, as general life expectancy is
      increasing.

      Nursing home residents with diabetes have higher rates of serious comorbidities and have
      greater activity of daily living dependencies than other residents without diabetes. In
      addition, persons with diabetes have higher risk of hypertension, heart disease, stroke
      depression, cognitive impairment, and cardiovascular mortality than individuals without
      diabetes.

      There are a few retrospective studies in elderly patients analyzing quality of diabetes care
      and glycemic control adjusted for medications and presence of co-morbidities in long-term
      care facilities; however, no previous randomized controlled trials have demonstrated benefits
      of glycemic control on clinical outcome, quality of life, and rate of acute metabolic
      complications (hyperglycemia and hypoglycemic events) in long-term care facilities. In
      addition, it is not known whether the use of basal insulin is superior to treatment with
      sliding scale insulin (SSI) in long-term care facility residents with type 2 diabetes.

      Accordingly, the investigators propose to conduct a prospective randomized control trial
      comparing the efficacy and safety of the basal (glargine) insulin regimen and sliding scale
      regular insulin in the management of nursing home patients with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL</measure>
    <time_frame>3 months</time_frame>
    <description>Mean weekly blood glucose concentration less than 70 mg/dL at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL</measure>
    <time_frame>3 months</time_frame>
    <description>Mean weekly blood glucose concentration less than 40 mg/dL at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean of Weekly Fasting Blood Glucose Concentration</measure>
    <time_frame>3 months</time_frame>
    <description>Mean weekly blood glucose concentration at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose Concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean blood glucose concentration at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Glycosylated Hemoglobin (hbA1c)</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Daily Blood Glucose Concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean of daily blood glucose concentration at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Glycosylated Hemoglobin (hbA1c)</measure>
    <time_frame>3 months</time_frame>
    <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Glycosylated Hemoglobin (hbA1c)</measure>
    <time_frame>6 months</time_frame>
    <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a person's blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes</condition>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>BASAL PLUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sliding scale regular insulin (SSRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>glargine once a day</description>
    <arm_group_label>BASAL PLUS</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>sliding scale regular insulin (SSRI) given before meals and at bedtime as needed</description>
    <arm_group_label>sliding scale regular insulin (SSRI)</arm_group_label>
    <other_name>Novolin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>glulisine given as needed before meals</description>
    <arm_group_label>BASAL PLUS</arm_group_label>
    <other_name>Apridra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females &gt; 60 years of age.

          2. Blood glucose &gt; 150 mg/dl and A1C &gt; 7.5%.

          3. A known history of T2DM, receiving either diet alone, oral monotherapy, or with any
             combination of oral antidiabetic agents (metformin, sulfonylureas, repaglinide,
             nateglinide, pioglitazone, rosiglitazone, sitagliptin).

          4. Patients admitted for non-cardiac elective or emergency surgery or trauma.

        Exclusion Criteria:

          1. Subjects with increased blood glucose concentration, but without a known history of
             diabetes (stress hyperglycemia).

          2. Subjects with a history of diabetic ketoacidosis and hyperosmolar hyperglycemic state
             (26).

          3. Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and
             portal hypertension), corticosteroid therapy, or impaired renal function (creatinine â‰¥
             3.5 mg/dl).

          4. Patients with recognized or suspected endocrine disorders associated with increased
             insulin resistance, acromegaly, or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory SOM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guillermo Umpierrez</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2010</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>December 18, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2014</results_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>elderly populations</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment took place at Emory University-Wesley Woods Campus between March 2011 through December 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>BASAL PLUS</title>
          <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
        </group>
        <group group_id="P2">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BASAL PLUS</title>
          <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
        </group>
        <group group_id="B2">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL</title>
        <description>Mean weekly blood glucose concentration less than 70 mg/dL at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL</title>
          <description>Mean weekly blood glucose concentration less than 70 mg/dL at 3 months</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL</title>
        <description>Mean weekly blood glucose concentration less than 40 mg/dL at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With a Mean Blood Glucose Concentration of Less Than 40 mg/dL</title>
          <description>Mean weekly blood glucose concentration less than 40 mg/dL at 3 months</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose Concentration</title>
        <description>Mean blood glucose concentration at baseline</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose Concentration</title>
          <description>Mean blood glucose concentration at baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.2" spread="39.7"/>
                    <measurement group_id="O2" value="191.8" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
        <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
          <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
          <units>percent of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="0.8"/>
                    <measurement group_id="O2" value="6.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Daily Blood Glucose Concentration</title>
        <description>Mean of daily blood glucose concentration at baseline</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Daily Blood Glucose Concentration</title>
          <description>Mean of daily blood glucose concentration at baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.0" spread="29.4"/>
                    <measurement group_id="O2" value="137.7" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
        <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
          <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
          <units>percent of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="1"/>
                    <measurement group_id="O2" value="6.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
        <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Glycosylated Hemoglobin (hbA1c)</title>
          <description>Mean glycosylated hemoglobin (hbA1c) at baseline. The A1C test result is reported as a percentage. The higher the percentage, the higher a personâ€™s blood glucose levels have been. A normal A1C level is below 5.7 percent.</description>
          <units>percent of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="1.1"/>
                    <measurement group_id="O2" value="6.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean of Weekly Fasting Blood Glucose Concentration</title>
        <description>Mean weekly blood glucose concentration at 3 months</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Plus</title>
            <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
          </group>
          <group group_id="O2">
            <title>Sliding Scale Regular Insulin (SSRI)</title>
            <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
          </group>
        </group_list>
        <measure>
          <title>Mean of Weekly Fasting Blood Glucose Concentration</title>
          <description>Mean weekly blood glucose concentration at 3 months</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="26"/>
                    <measurement group_id="O2" value="123" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BASAL PLUS</title>
          <description>Diabetic subjects receive glargine once daily plus corrective doses of glulisine before meals and bedtime as needed</description>
        </group>
        <group group_id="E2">
          <title>Sliding Scale Regular Insulin (SSRI)</title>
          <description>Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Severe Aortic Stenosis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ER visit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CV</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ARF</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>geumpie@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

